Eli Lilly is acquiring AtaiBeckley in a $2.8 billion cash deal, with up to $1 billion in additional contingent value rights (CVRs). The acquisition adds BPL-003, which holds FDA Breakthrough designation for treatment-resistant depression (TRD), to Lilly's pipeline. The deal is expected to close in Q3 2026.
This item was indexed from its published source and tied to the entity records it names. The Counterparty reports what the market says and who it says it about; it does not rewrite the original report. Read the source for the full account.